Journal of Capital Medical University ›› 2005, Vol. 26 ›› Issue (3): 270-273.

• 专题报道 • Previous Articles     Next Articles

Inhibitory Effects of Neovasculariztion by Jiangtangmingmu Capsule on Mouse Diabetic Retinopathy

Wang Jingjing1, Zhang Wei1, Lu Qingjun1,2, Li Wei1, Zhi Nan3   

  1. 1. Beijing Tongren Opthalmic Center, Beijing Tongren Hospital, Capital University of Medcial Sciences, Beijing Insitute of Ophthalmology;2. School of Ophthalmology, Capital University of Medical Sciences;3. Department of Traditional Medicine, Beijing Tongren Hospital, Capital University of Medical Sciences
  • Received:2005-05-19 Revised:1900-01-01 Online:2005-06-24 Published:2005-06-24

Abstract: Objective To observe the inhibition of neovascularization by jiangtangmingmu capsule on mouse diabetic retinopathy. Methods Male C57BL/B mice was injected with STZ to induce the diabetic mouse model, which was accepted to be nice model to study the diabetic retinopathy. Three groups were treated with serious doses of jiangtangmingmu capsule, the doses were 18, 9, 4.5 folds of clinical application respectively. Two positive treatment control groups were subjected with two other clinic approved medicine. Medicines were applied intragastric feeding daily. Serum glucose and body weight were observed periodically. After 80 d treatment, retina sections were stained by HE method and neovascular were counted under biological microscope. Results Diabetic mice induced by STZ were observed as raised serum glucose, and body weight lost significantly. Retina sections with HE stained were counted as increased neovascular numbers. All treated groups, including the serious doses of jiangtangmingmu capsule, two approved medicines, were observed as serum glucose decreasing and body weight increasing compared to the untreated diabetic mice. And the neovascular counting was decreased after the medicine treatment. Conclusion Jiangtangmingmu capsule can inhibit retinal neovascularization of diabetic mice induced by STZ.

Key words: jiangtangmingmu capsule, diabetic retinopathy, retinal neovascularization, serum glucose

CLC Number: